Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology ...

Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment ...

As a result of vertical integration, health plans may have 2 different coverage policies on the medical benefit side and the ...

At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on ...

Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well ...

Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much ...

Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of ...

Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk ...

Patients with schizophrenia have a lot of life-changing consequences when they are being treated properly, and these are only amplified when the patient goes untreated, explained Megan Ehret, PharmD, ...

The biosimilar market continued to grow, with 57 approved biosimilars and 17 reference product biologics as of June 2024. Biosimilars that have seen the fastest uptake have been in oncology, ...